Pyxis Oncology (NASDAQ: PYXS - Get Free Report) and Alumis (NASDAQ: ALMS - Get Free Report) are both

Alumis (NASDAQ: ALMS - Get Free Report) and Alvotech (NASDAQ: ALVO - Get Free Report) are both small

Alumis Inc. (ALMS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Bank of New York Mellon Corp acquired a new stake in Alumis Inc. (NASDAQ: ALMS) during the second qu

SOUTH SAN FRANCISCO, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-s

Oppenheimer analyst Jeff Jones maintains Alumis (NASDAQ:ALMS) with a Outperform and lowers the pr

Wells Fargo analyst Derek Archila maintains Alumis (NASDAQ:ALMS) with a Overweight and lowers the

U.S. stocks rose; Sirius XM jumped 5.5% after Deutsche Bank’s upgrade, while GitLab, Dell and other

Analysts upgraded Alumis, Sirius XM, OGE Energy, revising their price targets and outlooks.

Morgan Stanley analyst Terence Flynn maintains Alumis (NASDAQ:ALMS) with a Overweight and lowers

HC Wainwright & Co. analyst Mitchell S. Kapoor upgrades Alumis (NASDAQ:ALMS) from Neutral to

Alumis Inc. remains a late-stage biotech with no commercial product and significant risk. ALMS's val

Gainers bioAffinity Technologies (NASDAQ:BIAF) shares rose 43.1% to $6.53 during Tuesday's regu

Alumis Inc. (ALMS) Discusses Phase IIb LUMUS Trial Results and Subgroup Insights in Type 1 Interfero

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 100 poi

Alumis NASDAQ: ALMS said its Phase II LUMUS trial of envudeucitinib in systemic lupus erythematosus,

Alumis (ALMS) stock drops over 50% after Phase 2b lupus trial misses overall endpoints, but sub-grou

U.S. stocks traded lower this morning, with the Dow Jones index falling more than 300 points on Tues

Alumis said on Tuesday it plans to advance its experimental drug for a type of immunity-related cond

Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation target

– LUMUS trial did not meet its primary and secondary endpoints in the overall trial population – – R

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Alumis (NASDAQ:ALMS) with a Neutral

Alumis (NASDAQ:ALMS) reported quarterly losses of $(1.11) per share which missed the analyst consens

– ONWARD3: 54% of patients reached complete skin clearance (PASI 100) at 48 weeks, positioning envud

California State Teachers Retirement System boosted its holdings in shares of Alumis Inc. (NASDAQ: A

PTGX, ALMS, ORKA and VNDA offer diverse psoriasis opportunities, spanning approved therapies, late-s

Alumis Inc. (NASDAQ:ALMS) on Monday shared topline data from its ongoing ONWARD3 long-term extension

Alumis releases long-term data for psoriasis drug envudeucitinib, boasting top skin clearance rates

– Favorable long-term safety and tolerability profile remained consistent with previously reported d

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Alumis (NASDAQ:ALMS) with a Neutral

Alumis Inc. (NASDAQ: ALMS - Get Free Report)'s share price was up 5.7% on Friday. The company traded

Alumis receives a renewed Buy rating, driven by upcoming data catalysts for lead candidate envudeuci

This biotechnology firm develops clinical-stage therapies for autoimmune and neuroinflammatory disea

Chardan Capital analyst Janani Sundararajan maintains Alumis (NASDAQ:ALMS) with a Buy and raises

Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases through

Alumis Inc. develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases us

Top Wall Street analysts changed outlook on top names. DA Davidson initiated coverage on EBC & U

Top analysts changed outlook on top names. See all rating changes on analyst ratings page. Check out

– Late-breaking oral presentation of Phase 3 envudeucitinib data in moderate-to-severe plaque psoria

Top analysts changed ratings for OVV, ALMS, CLMT, LGN, RCKT, UTHR, VNT, HOOD. See full changes at be

Top Wall Street analysts changed outlook on top names. For all analyst rating changes, see analyst r

The Russell 2000 is beating the S&P 500 for 10 straight sessions as growth accelerates and small

Alumis Inc. is drawing attention with a major share sale and bullish analyst forecasts. The firm aim